Identifying Where Automation Can Improve Autologous CAR T Manufacturing Without Adding Complexity

In this first segment of our Cell & Gene Live, Automating Autologous CAR T Manufacturing: Lessons from Mayo Clinic, expert panelists Anthony DeFusco, M.S., Senior Director of Quality Control for the Center for Regenerative Biotherapeutics; Snigdha Rai, M.S., Senior Director of Biomanufacturing; and Cynthia Wilkins, Ph.D., M.B.A., Senior Director of Process Development and Assistant Professor of Regenerative Medicine, Mayo Clinic shared the biggest sources of variability and inefficiency in autologous CAR T manufacturing, including inconsistent patient starting material, manual operations, and the need for more reproducible processes. They also explored how developers should assess process complexity, establish appropriate controls, and determine whether modular or all-in-one automation platforms best fit their needs.